Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274273 | 0.84 | HCRTR2 (0.41) | TSHRSMYD3EPHX1KDM4EKMT2A | |
| SCHEMBL6672812 | 0.84 | HCRTR2 (0.41) | TSHRSMYD3EPHX1KDM4EKMT2A | |
| SCHEMBL30121548 | 0.84 | HCRTR2 (0.41) | TSHRSMYD3EPHX1KDM4EKMT2A | |
| SCHEMBL3713521 | 0.82 | SMYD3 (0.37) | SMYD3KDM4EKMT2A | |
| SCHEMBL2279016 | 0.82 | OPRM1 (0.41) | TSHRSMYD3KDM4EKMT2A | |
| SCHEMBL16365228 | 0.79 | TSHR (0.35) | TSHRSMYD3EPHX1SLC6A2SLC6A4 | |
| SCHEMBL23751101 | 0.75 | HCRTR2 (0.40) | TSHREPHX1KDM4EKMT2A | |
| SCHEMBL21564539 | 0.74 | CHRM1 (0.38) | TSHRSMYD3EPHX1KDM4EKMT2A | |
| SCHEMBL14919408 | 0.74 | IRAK4 (0.33) | SMYD3HSD17B10 | |
| SCHEMBL12070264 | 0.73 | HCRTR2 (0.43) | TSHRSMYD3EPHX1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2245033-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | TSHR 1966/4885SMYD3 3203/4885EPHX1 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.